Bortezomib as consolidation therapy in patients aged 60 years and younger with multiple myeloma

Trial Profile

Bortezomib as consolidation therapy in patients aged 60 years and younger with multiple myeloma

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs Bortezomib (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Janssen-Cilag
  • Most Recent Events

    • 06 Dec 2016 Results of pooled analysis of two trials (NCT00416273 and NCT00416208) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 14 Jun 2015 Results of pooled analysis of MMY3012 and MMY3013 trials presented at the 20th Congress of the European Haematology Association.
    • 02 Jun 2015 Results of pooled analysis of MMY3012 and MMY3013 trials presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top